U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H31NO4
Molecular Weight 397.5072
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DROTAVERINE

SMILES

CCOC1=CC=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1OCC

InChI

InChIKey=OMFNSKIUKYOYRG-MOSHPQCFSA-N
InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-

HIDE SMILES / InChI

Molecular Formula C24H31NO4
Molecular Weight 397.5072
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Drotaverine, an antispasmodic drug, is a synthetic derivative of the natural isoquinoline alkaloid of Papaver somniferum, papaverine. It inhibits cyclic-3',5'-nucleotide-phophodiesterase (PDE) enzymes with concentration-dependent specificity, in addition, it behaves as a L-type voltage- operated calcium channel (L-VOCC) blocker. Drotaverin also acts as a cytostatic compound for several human tumor cell lines. Drotaverine is an effective medicine to treat spasm or twitches of the smooth muscles in the stomach and heart. It is used to relieve pain caused due to irritable bowel syndrome, headache, menstrual periods, and is also used to relieve cervical spasm during labor.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
The drug is administered for interior use. 1-2 tablets (0.04—0.08 g) 2—3 time a day. In children under 6 0.01—0.02 g 1—2 times a day, in children of 6—12 years old — 0.02 g 1—2 times a day. In children after 12 the adult dose.
Route of Administration: Oral
In Vitro Use Guide
Drotaverin also acts as a cytostatic compound for several human tumor cell lines and nonmalignant mouse fibroblasts, and EC50 values as low as 3.0 μM were observed in SRB assays for HT-29 human colorectal carcinoma cells.
Substance Class Chemical
Record UNII
98QS4N58TW
Record Status Validated (UNII)
Record Version